Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
Authors:
- Mark N. LevineMLMark N. Levine
- Jim A. JulianJJJim A. Julian
- Philippe L. BedardPBPhilippe L. Bedard
- Andrea EisenAEAndrea Eisen
- Maureen E. TrudeauMTMaureen E. Trudeau
- Brian HigginsBHBrian Higgins
- Louise BordeleauLBLouise Bordeleau
- Kathleen I. PritchardKPKathleen I. Pritchard
- 1 April 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (10) , 1065-1071
Abstract
Purpose To evaluate the 21-gene recurrence score (RS) on decision-making in a population-based cohort. Patients and Methods Patients with axillary node-negative or nodal micrometastases, estrogen receptor–positive, and human epidermal growth factor receptor 2–negative breast cancer being considered for chemotherapy were eligible. All cancer treatment centers in Ontario, Canada, participated. Oncologists made a preliminary recommendation for endocrine therapy with or without chemotherapy on the basis of Adjuvant! Online (AOL) risk estimation. Patients were asked for their preference regarding chemotherapy. After RSs were available, patients returned for final decision-making. Patient satisfaction was measured by using the decisional conflict scale. Results Between January 2012 and July 2013, 1,000 patients were recruited. RSs were available for 979 patients. In 58% of patients, risk was categorized as low (RS, 0 to 18); in 33%, intermediate (RS, 19 to 30); and in 9%, high (RS, ≥ 31). Oncologists' recommendations pretest and post-test remained the same in 464 patients (48%), changed from unsure or chemotherapy to no chemotherapy in 365 (38%), and changed from unsure or no chemotherapy to chemotherapy in 143 (15%). After the test, oncologists recommended chemotherapy for 236 patients, 81% of whom received chemotherapy. Of 151 patients in whom risk was classified as intermediate by means of AOL, 41% were a low risk and 44% intermediate risk with RS. Of 298 patients at high risk with AOL, 16% had a high risk RS. None of 236 patients with grade I tumors had a high-risk RS. Mean total decisional conflict scale score significantly improved from pretest to post-test from 34 to 19 (P < .001). Conclusion The RS substantially influenced both oncologists' recommendations and patients' preferences for chemotherapy. The major effect was avoidance of chemotherapy when AOL indicated high or intermediate risk.Keywords
This publication has 24 references indexed in Scilit:
- Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009JAMA Oncology, 2015
- Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast CancerThe Oncologist, 2010
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC StudyJournal of Clinical Oncology, 2010
- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment SelectionJournal of Clinical Oncology, 2010
- Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancerCancer, 2007
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- S31 Toward a More Rational Selection of Tailored AdjuvantTherapy: Data from the National Surgical Adjuvant Breast and Bowel ProjectThe Breast, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast CancerJournal of Clinical Oncology, 2001
- Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast CancerJournal of Clinical Oncology, 2001